Bart C.H. van der Wal
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Bart C.H. van der Wal has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
- Edwin J. A. Veldhuizen
Division Infectious Diseases and Immunology, Department Biomolecular Health Sciences, Faculty of Veterinary Medicine, Utrecht University, Utrecht, The Netherlands
1 shared publication - Fatemeh Jahanmard
Department of Orthopedics University Medical Center Utrecht Utrecht 3508 GA The Netherlands
1 shared publication - Floris J. Bikker
Department of Oral Biochemistry, Academic Centre for Dentistry Amsterdam, University of Amsterdam and VU University Amsterdam, Amsterdam, The Netherlands
1 shared publication - H. Charles Vogely
Department of Orthopedics, University Medical Center Utrecht, Utrecht 3508GA, the Netherlands
1 shared publication - Harrie Weinans
University Medical Center Utrecht, Utrecht, The Netherlands
1 shared publication - Kamran Nazmi
Department of Oral Biochemistry, Academic Centre for Dentistry Amsterdam, University of Amsterdam and Vrije Universiteit Amsterdam, Gustav Mahlerlaan 3004, Amsterdam, 1081 LA, the Netherlands
1 shared publication
Latest Publications
- Open Access
- 2 August 2023
- Published by Wiley in Advanced Materials Technologies
- Vol. 8 (18)
Antibacterial CATH‐2 Peptide Coating to Prevent Bone Implant‐Related Infection
The development of antibacterial coatings is a promising approach to preventing biofilm formation and reducing the overuse of systemic antibiotics. However, widespread antibiotic use has resulted in antibiotic‐resistant bacteria, limiting the efficacy of antibiotic‐based coatings. Herein, an antibacterial coating is developed by layer‐by‐layer (LbL) assembly of two polymers namely PDLG (poly (D,L‐lactide‐co‐glycolide)) and gelatin methacryloyl (GelMA) while chicken cathelicidin‐2 (CATH‐2), a cationic and amphipathic peptide, is loaded between these polymer layers. The electrospray method is used to apply the coatings to achieve efficient peptide loading and durability. The CATH‐2 bactericidal concentration ranges are first identified, followed by a study of their cytotoxicity to human mesenchymal stem cells (hMSCs) and macrophage cell lines. Later, different LbL electrospray coating assemblies loaded with the optimal peptide concentration are sought. Various coating strategies are investigated to identify an LbL coating that exhibits prolonged and biocompatible CATH‐2 release. The resulting CATH‐2‐coated titanium surfaces exhibit strong antibacterial activity against both Staphylococcus aureus and Escherichia coli bacteria for 4 days and are biocompatible with hMSCs and macrophage cells. This coating can be considered as a versatile delivery system platform for the delivery of CATH‐2 peptides while avoiding cytotoxicity, particularly for the prevention of infections associated with implants.
- 2 August 2023
- Published by Wiley in Advanced Materials Technologies
- Vol. 8 (18)
Open AccessAntibacterial CATH‐2 Peptide Coating to Prevent Bone Implant‐Related Infection
The development of antibacterial coatings is a promising approach to preventing biofilm formation and reducing the overuse of systemic antibiotics. However, widespread antibiotic use has resulted in antibiotic‐resistant bacteria, limiting the efficacy of antibiotic‐based coatings. Herein, an antibacterial coating is developed by layer‐by‐layer (LbL) assembly of two polymers namely PDLG (poly (D,L‐lactide‐co‐glycolide)) and gelatin methacryloyl (GelMA) while chicken cathelicidin‐2 (CATH‐2), a cationic and amphipathic peptide, is loaded between these polymer layers. The electrospray method is used to apply the coatings to achieve efficient peptide loading and durability. The CATH‐2 bactericidal concentration ranges are first identified, followed by a study of their cytotoxicity to human mesenchymal stem cells (hMSCs) and macrophage cell lines. Later, different LbL electrospray coating assemblies loaded with the optimal peptide concentration are sought. Various coating strategies are investigated to identify an LbL coating that exhibits prolonged and biocompatible CATH‐2 release. The resulting CATH‐2‐coated titanium surfaces exhibit strong antibacterial activity against both Staphylococcus aureus and Escherichia coli bacteria for 4 days and are biocompatible with hMSCs and macrophage cells. This coating can be considered as a versatile delivery system platform for the delivery of CATH‐2 peptides while avoiding cytotoxicity, particularly for the prevention of infections associated with implants.